The presentations will focus on the performance of the company’s blood purification technology, CytoSorb, across a spectrum of critical care and surgical applications. At the EACTS meeting, researchers are slated to discuss intraoperative hemoadsorption techniques designed to mitigate bleeding risks in patients undergoing bypass surgery who are currently on dual antiplatelet or anticoagulant therapy. Additional sessions will examine real-world evidence from the international COSMOS registry, highlighting the device's role in managing postoperative vasoplegia and hyperinflammation during extracorporeal membrane oxygenation (ECMO) procedures.

Following the cardiac surgery sessions, the focus will shift to the ESICM LIVES congress, where data regarding the use of CytoSorb in intensive care settings will take center stage. Topics scheduled for review include liver support, respiratory distress management, and the treatment of septic shock. Dr. Phillip Chan, Chief Executive Officer of CytoSorbents, noted that the data underscores the utility of these purification methods in addressing life-threatening conditions where conventional treatment options remain limited. The findings are intended to refine clinical practices and further validate the role of hemoadsorption in complex, high-risk patient care.